OOIR: Observatory of International Research

Papers

(The H4-Index of ESMO Open is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆	244
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers	147
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN	136
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)	125
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update	103
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies	100
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials	97
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?	91
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment	89
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations	87
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts	87
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment	82
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of rando	82
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines	81
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era	80
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses	72
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies	72
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study	69
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis	67
Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis	66
How I treat biliary tract cancer	63
Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up	62
Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application	62
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort	61
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer	60

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer	57
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer	56
Targeting immunoliposomes to EGFR-positive glioblastoma	55
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer	54
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France	53
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer	52
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	48
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration	48
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer	48
Anti-TIGIT therapies for solid tumors: a systematic review	47
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical	46
How to use liquid biopsies to treat patients with cancer	46
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge	45
Consensus for HER2 alterations testing in non-small-cell lung cancer	44
Strategies to tackle RAS-mutated metastatic colorectal cancer	43
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring	43
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy	42